FOMAT Acquires Topography Health and Becomes the Largest Embedded Research Organization in the U.S.

What Is an Embedded Research Organization?

An Embedded Research Organization brings clinical trials directly into the physician practices where patients already receive their care. Instead of asking patients to travel to a research hospital or specialized facility, the ERO model makes trial participation available through the community doctors patients already know and trust.

This is not a new concept for FOMAT. The organization has spent more than a decade building and refining this model, maintaining rigorous standards of data quality, ethical oversight, and adherence to Good Clinical Practice across therapeutic areas ranging from gastroenterology to oncology to cardiovascular disease.

What makes this acquisition significant is scale. No other ERO in the United States operates at this level of geographic reach and site density — embedded in community settings, not academic institutions.

Topography Health: Technology That Makes Research Work for Physicians

Topography Health was built around a straightforward idea: clinical research should be manageable and even enjoyable for the physicians who conduct it. Using a combination of technology and support services, the company enabled community-based doctors to run clinical trials inside their own practices without disrupting the care they deliver daily.

That technology does not go away with this acquisition. It grows. Backed by FOMAT’s operational infrastructure, compliance framework, and national site network, Topography Health’s platform is positioned to reach significantly more physicians and patients across the country.

“This transaction allows us to expand our technology while ensuring that our research sites continue to deliver on the promise of bringing research to the patient — a shared mission with FOMAT. FOMAT’s scale and fully professionalized platform will only further deliver on this promise.”— Alexander Saint-Amand, Chief Executive Officer, Topography Health

What This Acquisition Changes for Sponsors and CROs

For pharmaceutical companies and contract research organizations evaluating site networks, this acquisition changes the picture in a meaningful way. FOMAT’s expanded network now offers:

• 35+ investigator sites embedded in community practices across six states
• Access to diverse and underserved patient populations that are historically underrepresented in clinical studies
• Infrastructure to support Phase I through Phase IV studies across multiple therapeutic areas
• Stronger enrollment performance driven by trusted physician-patient relationships built over years of care
• Combined operational scale with therapeutic expertise in a single, professionalized platform

What This Means for Community Physicians

Physicians who want to offer their patients access to clinical trials often face a significant hurdle: the infrastructure needed to conduct research is complex, expensive, and time-consuming to build from scratch. FOMAT removes that barrier entirely.

Through the expanded network, community physicians across the six-state footprint — and beyond as the organization grows — have access to a fully professionalized platform that handles the operational, regulatory, and logistical complexity of clinical research, so physicians can focus on what they do best: caring for patients.

What This Means for Patients

The most important measure of this acquisition is whether it puts more patients in more communities within reach of clinical trials. The answer is yes — and at a scale that has not existed before in the embedded research model.

Patients in Maryland, California, Colorado, New Mexico, Michigan, and Virginia can now access innovative research therapies through their own community physicians, in the practices where they already receive care. As FOMAT continues to grow, that reach will extend further.

Clinical research should reflect the real world. That starts with making it available where real patients live.